Navigation Links
AlphaRx and Gaia BioPharma Report Positive Efficacy Results in a Pre-Clinical Trial of GAI-122 Injectable Nano-emulsion for Post-operative Delirium
Date:6/29/2009

    GAI-122, an investigational injectable nanoemulsion formulated with
    AlphaRx's proprietary drug delivery technology, providing significant
    neuro-protection in multiple in vitro and in vivo studies which suggest
    that this injectable nanoemulsion formulation has the potential to
    prevent postoperative delirium

MARKHAM, ON, June 29 /PRNewswire-FirstCall/ - AlphaRx Inc. (OTCBB: ALRX) and Gaia BioPharma Limited today reported positive pre-clinical results on GAI-122 injectable nanoemulsion in multiple in vitro and in vivo studies of memory impairment after prolonged anesthesia.

Delirium is a common mental disorder with serious adverse outcomes in post-operative hospitalized patients. It is associated with an increase in mortality, physical morbidity, length of hospital stay, institutionalization of patients and increased cost to healthcare providers. Ten to thirty percent of admissions of patients over 65 years of age to a general hospitals develop delirium after surgery and the incidence rate can be as high as 50% in patients who undergone high risk and lengthy procedures such as hip replacement and cardiac surgeries. There is no preventive therapy currently available for post-operative delirium.

"There are over 10,000,000 inpatient surgeries performed annually in the U.S. on patients over the age of 65, and up to 40% of these seniors will develop post-operative delirium. There is an urgent need to develop a medicine, such as GAI-122 injectable nanoemulsion, for the preventive of this debilitating post-operative condition," said Dr. Michael Weisspapir, MD, PhD, Chief Medical Scientist of AlphaRx.

In rat model studies, injected GAI-122 ameliorates learning and memory disturbances produced by cerebral embolization, cerebral ischemia or lesions in the basal forebrain, the area of origin of the acetylcholine neuron system projecting into the cerebral cortex, hippocampus and amygdala. In clinical tests, an oral form of GAI-122 has been shown to be effective in psychological deficits such as a decline in memory retention and disorientation.

In October 2008, AlphaRx licensed GAI-122 to Gaia BioPharma. Under the terms of the amended agreement, AlphaRx is eligible to receive milestone payments of up to $50 million for the successful development and commercialization of GAI-122, as well as royalties on worldwide sales. In addition, Gaia BioPharma has assumed all development costs.

About AlphaRx Inc.

AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific nano drug delivery technology, offers improved medical benefits and a potential for significant commercial product development.

About Gaia BioPharma

Gaia BioPharma Limited, a privately held, early stage biopharmaceutical company focused on hospital-based injectable therapeutics. Gaia BioPharma seeks to address key unmet therapeutic needs by taking established compounds and changing their administration routes to create patent-protected, value-added products.

FORWARD LOOKING STATEMENTS:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.


'/>"/>
SOURCE AlphaRx Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. AlphaRx Shareholder Update
2. AlphaRx and Gaia BioPharma Provide GAI-122 Development Update
3. AlphaRx Signs Cooperative Research and Development Agreement with US Army
4. AlphaRx Provides Corporate and Development Update
5. AlphaRxs Indaflex(TM) Continues its Clinical Development
6. AlphaRx CEO Accumulates More Company Shares
7. AlphaRx Officers and Directors To Exercise Options, Warrants and Retain Shares
8. AlphaRx Announces Debt Conversion
9. AlphaRx To Present at 47th Annual ICAAC
10. Helix Biopharma Corp. Begins Trading on the OTCQX International Market Listing as HXBPF
11. Sinobiopharma Receives Trademark Approval and Authentication From Chinese Government For Its Tai Drug Series
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... ... 01, 2017 , ... Financial Recovery Group, Inc. (FRG), is proud to announce ... Nashville, Tenn. The company also is offering a special discount for those who attend ... year, brings together the brightest minds in the healthcare industry to share information on ...
(Date:3/1/2017)... ... March 01, 2017 , ... Look for a new collection of ... and Drift Roses. Star Roses and Plants is launching their new Bushel and ... Bushel and Berry Collection makes growing fresh fruit simple with a variety of easy-to-grow, ...
(Date:3/1/2017)... , ... March 01, 2017 , ... On January 27, ... Firm, filed a civil sex abuse lawsuit in the Circuit Court of Kanawha County, ... have only been identified by their initials. See L.B. and T.B. v. Seventh-Day Adventist ...
(Date:3/1/2017)... , ... March 01, 2017 , ... Award-winning medical group ... 25 medical mission trips in underdeveloped nations, averaging more than one trip per year ... article on the website features the details of his charitable work. Char ...
(Date:3/1/2017)... ... 2017 , ... NYC based Integrated practice Living Well Medical, a long time ... of Orthopaedic Surgeon Dr. Donald E. Heitman. Dr. Heitman is a native ... Bachelor of Science degree in biology. He then obtained his medical degree from New ...
Breaking Medicine News(10 mins):
(Date:3/1/2017)... Sun Chlorella Corp ., the California -based ... Non-GMO Project Verification and the launch of individual serving packets ... for the Natural Products Expo West trade show, March 10-12 ... Chlorella Corp. has announced the Non-GMO Project Verification logo is ... Sun Chlorella tablets, 250mg and 500mg (20/100-day supplies) ...
(Date:3/1/2017)... March 1, 2017  Integrated Modular Design ... design and implementation of pre-fabricated healthcare products ... room headwalls, seeks to lead the construction ... solutions. Fueled by their leading-edge ... of reducing construction timelines and project risk, ...
(Date:3/1/2017)... , March 1, 2017  Global biotherapeutics leader ... the largest ever Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) trial, ... T reatment with H izentra ® ).  ... the efficacy, safety and tolerability of two different doses ... (Immune Globulin Subcutaneous [Human]), compared with placebo, in the ...
Breaking Medicine Technology: